Amylyx Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $3.23M, a 5566.67% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $428.00K, a 650.88% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $2.00K, a 91.30% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $57.00K, a 61.22% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $774.00K, a 136.70% increase from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $327.00K, a 94.29% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $5.72M, a 161.53% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $2.19M, a 538.19% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $3.23M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $774.00K 10-K · filed 2026-03-03 | |
| 2025-09-30 | $428.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $2.00K 10-Q · filed 2025-11-06 | |
| 2025-03-31 | $57.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $327.00K 10-K · filed 2026-03-03 | |
| 2024-09-30 | $57.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $23.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $147.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $5.72M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $938.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.69M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $2.78M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $2.19M 10-K · filed 2024-02-22 | |
| 2022-06-30 | $248.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $196.38M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $343.00K 10-K · filed 2024-02-22 | |
| 2021-09-30 | $164.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $3.00K 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $31.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |